Low plasma uric acid level in Parkinson's disease
Identifieur interne : 002D64 ( Main/Exploration ); précédent : 002D63; suivant : 002D65Low plasma uric acid level in Parkinson's disease
Auteurs : Tua Annanmaki [Finlande] ; Antti Muuronen [Finlande] ; Kari Murros [Finlande]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-06-15.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (therapeutic use), Body Mass Index, Energy Intake, Female, Ferritin, Ferritins (blood), Humans, Levodopa (therapeutic use), Male, Mass Screening, Middle Aged, Nervous system diseases, Parkinson Disease (blood), Parkinson Disease (drug therapy), Parkinson Disease (epidemiology), Parkinson disease, Parkinson's disease, Plasma, Risk Factors, Selegiline (therapeutic use), Spouses, Uric Acid (blood), Uric acid, diet, ferritin, uric acid.
- MESH :
- chemical , blood : Ferritins, Uric Acid.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa, Selegiline.
- blood : Parkinson Disease.
- drug therapy : Parkinson Disease.
- epidemiology : Parkinson Disease.
- Aged, Body Mass Index, Energy Intake, Female, Humans, Male, Mass Screening, Middle Aged, Plasma, Risk Factors, Spouses.
Abstract
Earlier studies suggest that low plasma uric acid level is a risk factor for Parkinson's disease (PD), and that uric acid associates with iron‐binding proteins. We therefore decided to examine plasma uric acid levels and markers of peripheral iron metabolism in PD patients and healthy controls. For the study, 40 patients with PD and 29 controls underwent clinical screening, laboratory testing, and body mass index (BMI) measurement. The average consumption of different foodstuffs and dairy products was estimated. Plasma uric acid level was significantly lower in the patients than in the controls. There were no significant differences in the levels of plasma iron parameters, but plasma uric acid correlated strongly with serum ferritin both in the patient and the control group. The BMI was slightly lower in the patients compared with the controls despite equal daily calorie consumption. Plasma uric acid level is low in patients with PD, which may have implications for both the disease pathogenesis and treatment recommendations. © 2007 Movement Disorder Society
Url:
DOI: 10.1002/mds.21502
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 002903
- to stream Istex, to step Curation: 002903
- to stream Istex, to step Checkpoint: 001872
- to stream PubMed, to step Corpus: 002763
- to stream PubMed, to step Curation: 002763
- to stream PubMed, to step Checkpoint: 002736
- to stream Ncbi, to step Merge: 001B76
- to stream Ncbi, to step Curation: 001B76
- to stream Ncbi, to step Checkpoint: 001B76
- to stream Main, to step Merge: 003C86
- to stream PascalFrancis, to step Corpus: 001643
- to stream PascalFrancis, to step Curation: 001678
- to stream PascalFrancis, to step Checkpoint: 001607
- to stream Main, to step Merge: 004197
- to stream Main, to step Curation: 002D64
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Low plasma uric acid level in Parkinson's disease</title>
<author><name sortKey="Annanmaki, Tua" sort="Annanmaki, Tua" uniqKey="Annanmaki T" first="Tua" last="Annanmaki">Tua Annanmaki</name>
</author>
<author><name sortKey="Muuronen, Antti" sort="Muuronen, Antti" uniqKey="Muuronen A" first="Antti" last="Muuronen">Antti Muuronen</name>
</author>
<author><name sortKey="Murros, Kari" sort="Murros, Kari" uniqKey="Murros K" first="Kari" last="Murros">Kari Murros</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:81727F9C029FF932F5F6E87CE544E291A7BDFDA2</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1002/mds.21502</idno>
<idno type="url">https://api.istex.fr/document/81727F9C029FF932F5F6E87CE544E291A7BDFDA2/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002903</idno>
<idno type="wicri:Area/Istex/Curation">002903</idno>
<idno type="wicri:Area/Istex/Checkpoint">001872</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Annanmaki T:low:plasma:uric</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:17443703</idno>
<idno type="wicri:Area/PubMed/Corpus">002763</idno>
<idno type="wicri:Area/PubMed/Curation">002763</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002736</idno>
<idno type="wicri:Area/Ncbi/Merge">001B76</idno>
<idno type="wicri:Area/Ncbi/Curation">001B76</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001B76</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Annanmaki T:low:plasma:uric</idno>
<idno type="wicri:Area/Main/Merge">003C86</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0349116</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001643</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001678</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001607</idno>
<idno type="wicri:doubleKey">0885-3185:2007:Annanmaki T:low:plasma:uric</idno>
<idno type="wicri:Area/Main/Merge">004197</idno>
<idno type="wicri:Area/Main/Curation">002D64</idno>
<idno type="wicri:Area/Main/Exploration">002D64</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Low plasma uric acid level in Parkinson's disease</title>
<author><name sortKey="Annanmaki, Tua" sort="Annanmaki, Tua" uniqKey="Annanmaki T" first="Tua" last="Annanmaki">Tua Annanmaki</name>
<affiliation wicri:level="1"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology of Jorvi Hospital, Helsinki University Hospital, Helsinki</wicri:regionArea>
<wicri:noRegion>Helsinki</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Muuronen, Antti" sort="Muuronen, Antti" uniqKey="Muuronen A" first="Antti" last="Muuronen">Antti Muuronen</name>
<affiliation wicri:level="1"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology of Jorvi Hospital, Helsinki University Hospital, Helsinki</wicri:regionArea>
<wicri:noRegion>Helsinki</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Murros, Kari" sort="Murros, Kari" uniqKey="Murros K" first="Kari" last="Murros">Kari Murros</name>
<affiliation wicri:level="1"><country xml:lang="fr">Finlande</country>
<wicri:regionArea>Department of Neurology of Jorvi Hospital, Helsinki University Hospital, Helsinki</wicri:regionArea>
<wicri:noRegion>Helsinki</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2007-06-15">2007-06-15</date>
<biblScope unit="vol">22</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1133">1133</biblScope>
<biblScope unit="page" to="1137">1137</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">81727F9C029FF932F5F6E87CE544E291A7BDFDA2</idno>
<idno type="DOI">10.1002/mds.21502</idno>
<idno type="ArticleID">MDS21502</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Body Mass Index</term>
<term>Energy Intake</term>
<term>Female</term>
<term>Ferritin</term>
<term>Ferritins (blood)</term>
<term>Humans</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Mass Screening</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (epidemiology)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Plasma</term>
<term>Risk Factors</term>
<term>Selegiline (therapeutic use)</term>
<term>Spouses</term>
<term>Uric Acid (blood)</term>
<term>Uric acid</term>
<term>diet</term>
<term>ferritin</term>
<term>uric acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Ferritins</term>
<term>Uric Acid</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Body Mass Index</term>
<term>Energy Intake</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Mass Screening</term>
<term>Middle Aged</term>
<term>Plasma</term>
<term>Risk Factors</term>
<term>Spouses</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Ferritine</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Urique acide</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Earlier studies suggest that low plasma uric acid level is a risk factor for Parkinson's disease (PD), and that uric acid associates with iron‐binding proteins. We therefore decided to examine plasma uric acid levels and markers of peripheral iron metabolism in PD patients and healthy controls. For the study, 40 patients with PD and 29 controls underwent clinical screening, laboratory testing, and body mass index (BMI) measurement. The average consumption of different foodstuffs and dairy products was estimated. Plasma uric acid level was significantly lower in the patients than in the controls. There were no significant differences in the levels of plasma iron parameters, but plasma uric acid correlated strongly with serum ferritin both in the patient and the control group. The BMI was slightly lower in the patients compared with the controls despite equal daily calorie consumption. Plasma uric acid level is low in patients with PD, which may have implications for both the disease pathogenesis and treatment recommendations. © 2007 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Finlande</li>
</country>
</list>
<tree><country name="Finlande"><noRegion><name sortKey="Annanmaki, Tua" sort="Annanmaki, Tua" uniqKey="Annanmaki T" first="Tua" last="Annanmaki">Tua Annanmaki</name>
</noRegion>
<name sortKey="Murros, Kari" sort="Murros, Kari" uniqKey="Murros K" first="Kari" last="Murros">Kari Murros</name>
<name sortKey="Muuronen, Antti" sort="Muuronen, Antti" uniqKey="Muuronen A" first="Antti" last="Muuronen">Antti Muuronen</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002D64 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002D64 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:81727F9C029FF932F5F6E87CE544E291A7BDFDA2 |texte= Low plasma uric acid level in Parkinson's disease }}
This area was generated with Dilib version V0.6.23. |